WITHDRAWN: Kdm5a promotes B cell activation in systemic lupus erythematosus via downregulation of A20 by histone modification

Fan, Jie; Iwata, S.; Tanaka, Yoshiya; Kitanaga, Yukihiro; Ishii, Atsushi; Maiko, Hara; Zhang, Xueqiang; Liu, Xingde

doi:10.1016/j.prp.2021.153653

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kool et al reported that A20-deficient Dendritic cells were resistant to apoptosis, caused by upregulation of antiapoptotic proteins Bcl-2 and Bcl-x, which can be transcriptional regulated by NF-κB ( Kool et al, 2011 ). A similar phenomenon was found in A20-deficient B cells and Nasopharyngeal Carcinoma cells ( Tavares et al, 2010 ; Zheng et al, 2017 ; Fan et al, 2021 ). Another study suggested that elevated A20 can stabilize the ripoptosome and potentiate its apoptosis-inducing activity, thereby, promote the RIPK1-dependent apoptosis in intestinal epithelial cells ( Garcia-Carbonell et al, 2018 ).…”

Section: Introductionsupporting

confidence: 77%

Advances in the Study of the Ubiquitin-Editing Enzyme A20

Bai

Huo

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Ubiquitin modification is a common post-translational protein modification and an important mechanism whereby the body regulates protein levels and functions. As a common enzyme associated with ubiquitin modification, the ubiquitin-editing enzyme A20 may be closely associated with the development of numerous pathological processes through its different structural domains. The aim of this paper is to provide an overview of the following: advances in ubiquitination research, the structure and function of A20, and the relationships between A20 and immune inflammatory response, apoptosis, necroptosis, pyroptosis, and autophagy.

show abstract

Section: Introductionsupporting

confidence: 77%

Advances in the Study of the Ubiquitin-Editing Enzyme A20

Bai

Huo

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

WITHDRAWN: Acute cerebral infarction patients' 3-month mortality predicted by peripheral tumor necrosis factor alpha-induced protein 3 mRNA level

Huang

Zhang

Zhu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Tumor necrosis factor-induced protein 3 (A20) is a novel negative regulator of immunological homeostasis. This research aimed to determine whether A20 mRNA in peripheral blood mononuclear cells (PBMCs) could be used to predict 3-month functional outcome and mortality in individuals with acute cerebral infarction (ACI). Methods There were 50 healthy controls and 182 patients with ACI in this study. Real-time quantitative polymerase chain reaction was performed to detect the A20 mRNA expression levels in PBMCs from ACI patients and healthy controls.We also recorded the medical history, score of National Institutes of Health Stroke Scale score on the first day of disease onset (NIHSS1), cranial magnetic resonance imaging findings, and hematological examination index. On day 90 after disease onset, the prognosis was evaluated using a modified Rankin scale. Results In comparison to healthy controls, the median A20 mRNA levels in PBMCs of ACI patients were considerably greater (P < 0.001). A20 mRNA expression levels in PBMCs were negatively correlated with lesion volume (r = -0.1678, P < 0.05) and NIHSS1 score (r = -0.2897, P < 0.0001). A20 mRNA expression levels were substantially greater in the survivor group and the groups with favorable outcomes, respectively compared to those in the non-survivor group (P < 0.005) and the groups with unfavorable outcome (P < 0.05). Conclusion A20 mRNA is involved in the immune response in ACI and might be a potential biomarker of ACI-related mortality.

show abstract

WITHDRAWN: Acute cerebral infarction patients' 3-month mortality predicted by peripheral tumor necrosis factor alpha-induced protein 3 mRNA level

2023

Preprint

View full text Add to dashboard Cite

show abstract

WITHDRAWN: Kdm5a promotes B cell activation in systemic lupus erythematosus via downregulation of A20 by histone modification

Cited by 3 publications

References 30 publications

Advances in the Study of the Ubiquitin-Editing Enzyme A20

Advances in the Study of the Ubiquitin-Editing Enzyme A20

WITHDRAWN: Acute cerebral infarction patients' 3-month mortality predicted by peripheral tumor necrosis factor alpha-induced protein 3 mRNA level

WITHDRAWN: Acute cerebral infarction patients' 3-month mortality predicted by peripheral tumor necrosis factor alpha-induced protein 3 mRNA level

Contact Info

Product

Resources

About